GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer ; volume:21 ; number:1 ; day:13 ; month:8 ; year:2023 ; pages:1-4 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (13.8.2023), 1-4, 12.2023
- Creator
-
Mei, Jie
Cai, Yun
Jiang, Guanyu
He, Zhao
Wang, Ruixin
Song, Chenghu
Wan, Yuan
Mao, Wenjun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04415-w
- URN
-
urn:nbn:de:101:1-2023110309415096695809
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:53 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mei, Jie
- Cai, Yun
- Jiang, Guanyu
- He, Zhao
- Wang, Ruixin
- Song, Chenghu
- Wan, Yuan
- Mao, Wenjun
- SpringerLink (Online service)
Other Objects (12)
Physical exercise reverses immuno-cold tumor microenvironment via inhibiting SQLE in non-small cell lung cancer
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Comprehensive characterization of B7 family members in breast cancer: B7-H5 switch reverses breast cancer from “immuno-cold” into “immuno-hot” status
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
Physical exercise reverses immuno-cold tumor microenvironment via inhibiting SQLE in non-small cell lung cancer
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Comprehensive characterization of B7 family members in breast cancer: B7-H5 switch reverses breast cancer from “immuno-cold” into “immuno-hot” status
EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer
Physical exercise reverses immuno-cold tumor microenvironment via inhibiting SQLE in non-small cell lung cancer
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Salvage surgery following immuno-chemo-radiotherapy for advanced non-small cell lung cancer
TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer
Immuno-oncology
Immuno-Oncology
ImmunoMedicine
Comprehensive characterization of B7 family members in breast cancer: B7-H5 switch reverses breast cancer from “immuno-cold” into “immuno-hot” status